ASCO 2019 | TNBC: the targeted therapy era

Adam Brufsky

Adam Brufsky, MD, PhD, of the University of Pittsburgh Medical Center. Pittsburgh, PA, tells us about the progress we are seeing in the triple-negative breast cancer (TNBC) field with the rise of targeted agents. Speaking at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL, Dr Brufsky goes on to discuss upcoming trials in the field that he is excited for.

Share this video